Bevacizumab-Induced Reversible Thrombocytopenia in a Patient with Adenocarcinoma of Colon: Rare Adverse Effect of Bevacizumab
We report a case of bevacizumab- (BEV-) induced thrombocytopenia in a 59-year-old man with adenocarcinoma of colon. After colectomy, the patient was treated with twelve cycles of FOLFOX-4 (folinic acid, 5-fluorouracil, and oxaliplatin) regimen. On relapse, he was treated with FOLFIRI (folinic acid,...
Saved in:
Main Authors: | Jeevan Kumar, Manorama Bhargava, Shyam Aggarwal |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2012-01-01
|
Series: | Case Reports in Oncological Medicine |
Online Access: | http://dx.doi.org/10.1155/2012/695430 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Bevacizumab: A Rare Cause of Nonischemic Cardiomyopathy
by: Oreoluwa Oladiran, et al.
Published: (2018-01-01) -
Complete Disappearance of Choroidal Metastasis from Lung Adenocarcinoma Treated with Bevacizumab and Chemotherapy
by: Hampig Raphael Kourie, et al.
Published: (2015-01-01) -
The Effect of Bevacizumab and Propranolol on Nasal Polyposis
by: Yuksel Olgun, et al.
Published: (2022-01-01) -
Photopsias during Systemic Bevacizumab Therapy
by: Heather Leisy, et al.
Published: (2016-01-01) -
In Vitro Study of Combined Application of Bevacizumab and 5-Fluorouracil or Bevacizumab and Mitomycin C to Inhibit Scar Formation in Glaucoma Filtration Surgery
by: Yuanyuan Zhang, et al.
Published: (2019-01-01)